<DOC>
	<DOCNO>NCT00003780</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Biological therapy use different way stimulate immune system stop cancer cell grow . It yet know whether chemotherapy effective biological therapy treat patient cancer pancreas . PURPOSE : Randomized phase II trial compare effectiveness gemcitabine biological therapy treat patient cancer pancreas surgically remove .</brief_summary>
	<brief_title>Chemotherapy Compared Biological Therapy Treating Patients With Cancer Pancreas</brief_title>
	<detailed_description>OBJECTIVES : I . Compare efficacy CYTOIMPLANT ( intratumor implant allogeneic peripheral blood mononuclear cell sensitize patient alloantigens mixed lymphocyte culture ) v gemcitabine patient unresectable , locally advanced metastatic pancreatic cancer . II . Compare overall survival , progression free survival , objective tumor response , time treatment failure , quality life patient . III . Compare safety toxicity CYTOIMPLANT v gemcitabine patient . OUTLINE : This randomize , open label , multicenter study . Patients randomly assign ( 2:1 ratio favor CYTOIMPLANT arm ) one two treatment arm . Arm I : Patients receive gemcitabine IV weekly 7 week , follow 1 week rest . In subsequent course , patient receive gemcitabine IV weekly 3 week follow week rest . Courses repeat every 4 week absence disease progression unacceptable toxicity . Arm II : Patients undergo leukapheresis collect lymphocytes . Patient lymphocytes mixed donor lymphocytes sponsor lab . The mixture implant tumor use endoscopic ultrasound guide fine needle injection . This process may repeat fifth month use different donor 's lymphocyte . Follow assessment may include physical exam , lab test , CT scan , quality life assessment 4 week 3 , 5 , 7 , 9 , 12 month date randomization . Patients contact every 3 month assess status . PROJECTED ACCRUAL : A total 150 patient accrue study .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven stage II , III , IV pancreatic cancer unresectable No symptomatic third space fluid collection ( e.g. , ascites , pleural effusion ) PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : At least 3 month Hematopoietic : WBC least 3,500/mm3 Platelet count least 100,000/mm3 Hematocrit least 33 % Hemoglobin least 10.5 g/dL Hepatic : Bilirubin great 3.0 mg/dL SGOT SGPT great 3 time upper limit normal Renal : Creatinine great 1.5 mg/dL Cardiovascular : No history myocardial infarction within past 3 month No congestive heart failure Other : HIV negative No prior malignancy except basal cell skin cancer No persistent fever great 102 degree F ( 39 degree C ) unless cause pancreatic cancer Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior biologic therapy ( e.g. , interferon , interleukin ) Chemotherapy : No prior chemotherapy Endocrine therapy : No concurrent systemic steroid Radiotherapy : No prior radiotherapy Surgery : At least 30 day since prior surgery Decompressive surgery endoscopic stenting ( include expandable wire stent ) allow relieve symptom disease Other : At least 30 day since prior investigational therapy Palliative care relieve symptom disease allow , include pain management celiac block endoscopic ultrasonography percutaneously</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>